• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Danish biotech company announce the completion of a €5.5 million seed investment

Bioengineer by Bioengineer
March 22, 2019
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The big Chinese fine chemical company Zhejiang NHU invest €5.5 million in the biotech start-up CysBio to develop new and affordable biochemicals

IMAGE

Credit: The Novo Nordisk Foundation Center for Biosustainability (DTU)/CysBio

CysBio is making cost-effective and novel biochemicals via sustainable fermentation processes. Through advanced synthetic biology and metabolic engineering approaches microorganisms are engineered to convert simple sugars into desired biochemical products. This makes it possible to produce expensive chemicals at very attractive cost levels and furthermore enables the production of novel or rare biochemicals.

The products will have applications in a variety of areas such as the food, feed, nutrition, pharma, cosmetics, and polymer industries.

“Our technologies enable CysBio to create some of the cheapest biochemicals available, as well as some very exciting new products with novel applications as functional chemical building blocks,” says Alex Toftgaard Nielsen, CSO and Co-founder of CysBio and Professor at DTU Biosustain.

Based on scientific research from DTU

CysBio’s technologies are patented and based on scientific research conducted at the Novo Nordisk Foundation Center for Biosustainability at the Technical University of Denmark. This research has made it possible to modify and engineer the bacteria’s metabolism, thus, making them able to produce specific amino acids and sulfated biochemicals.

“The investment from NHU demonstrates how DTU’s innovation eco-system has successfully assisted in translating academic research into a privately funded spin-out company with a strong technology platform,” says Marianne Thellersen, Senior Vice President for Innovation and Entrepreneurship at DTU.

Big unexploited potential

The technology platform paves the way for producing compounds used for e.g. new polymer materials with new functionalities such as conductivity and adhesiveness. Products that are highly demanded by the chemical industry. One of the other biochemicals that CysBio works with is well-known from nature as an alternative to chemically produced pesticides to prevent the growth of bacteria and fungus on surfaces of various kinds. Thus, CysBio expects to produce greener alternatives that can replace the use of harsh chemicals in many different market segments.

“We aim at becoming a leading provider of functional biochemical monomers and the partnership with a leading company like Zhejiang NHU will allow a fast market introduction of parts of this technology. Our strategy will clearly be to enables our technologies to be exploited quickly and effectively through R&D and commercial partnerships,” says Henrik Meyer, CEO and Co-founder of CysBio.

The Danish biotech company plans to get their first products on the market already at the beginning of 2020.

Future perspectives for pharma

Some of the key targets for the proprietary sulfation technology will be methods for improving the solubility and bioavailability of some existing drugs and nutraceuticals, thereby increasing the efficacy of the drugs.

“This will help in solving the problem of developing new pharmaceuticals, so we also see great potential in collaborating closely with partners in the pharma industry, “says Alex Toftgaard Nielsen.

Expands portfolio of products

For the stock listed Chinese chemical company, Zhejiang NHU, with global operations and subsidiaries in Europe, the seed investment in CysBio also opens up for exploring new opportunities in the market.

“We strongly believe the future of biotechnology. We have great strategic interests in expanding our biotechnology-based product portfolio by partnering with biotechnology companies. We look forward to assisting CysBio in their growth and further product development.” says Mr. Bai Fan Hu, Chairman of Zhejiang NHU.

###

Media Contact
Anders Osterby Moensted
[email protected]

Tags: BiochemistryBiologyBiomedical/Environmental/Chemical EngineeringBiotechnologyCollaborationGrants/FundingIndustrial Engineering/Chemistry
Share12Tweet8Share2ShareShareShare2

Related Posts

Innovative Acid-Base Bifunctional Catalyst Enhances Production of Essential Lithium-Ion Battery Material

Innovative Acid-Base Bifunctional Catalyst Enhances Production of Essential Lithium-Ion Battery Material

August 1, 2025
Oven-Temperature Treatment (~300℃) Enhances Catalyst Performance by Six Times

Oven-Temperature Treatment (~300℃) Enhances Catalyst Performance by Six Times

August 1, 2025

5 Innovations Securing Water Sources and Ensuring Availability

August 1, 2025

Innovative Imaging Technique Reveals Elemental Distributions in Frozen Solvents within Nanomaterials

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    43 shares
    Share 17 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Lorlatinib’s Real-World Impact on ALK+ NSCLC

TrueBeam vs. Halcyon: Breast Cancer Radiotherapy Comparison

Magnesium Implants Boost Bone-Immune Health In Vitro

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.